Hydroxyester Derivatives Inhibiting Bcl-2 Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compounds to inhibit anti-apoptotic activity of the Bcl-2 family proteins, which are overexpressed in various cancers and contribute to tumorigenesis and chemoresistance.
Innovation Solution
Development of new hydroxyester derivatives with pro-apoptotic properties that specifically target and inhibit the anti-apoptotic activity of Bcl-2 family proteins, potentially reactivating the apoptotic process in cancerous cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of cancer is attempted, but they fail to effectively inhibit anti-apoptotic activity of Bcl-2 family proteins
Solution Approach 1:
The patent develops novel hydroxyester derivatives with specific molecular structures (formula I) that change the chemical parameters of apoptosis-inducing compounds. These compounds are designed to specifically bind to and inhibit Bcl-2 family proteins, overcoming the limitations of current therapies that cannot effectively target these anti-apoptotic proteins.
2Reliability
If new hydroxyester derivatives are developed to target Bcl-2 family proteins, then pro-apoptotic activity is achieved, but the complexity of the chemical structure increases
Solution Approach 1:
The hydroxyester derivatives are designed with segmented molecular structures consisting of distinct functional groups (formula I). The molecule is divided into key structural elements including the hydroxyester group, aromatic rings, and substituent groups that can be independently optimized. This segmentation allows for systematic structure-activity relationship studies while maintaining manageable synthetic complexity.
3Adaptability or versatility
If compounds are designed to reactivate apoptosis in cancerous cells, then therapeutic potential against chemo-resistant cancers is achieved, but the selectivity and specificity requirements increase
Solution Approach 1:
The patent introduces specific local structural features in the hydroxyester derivatives, including particular substituent groups at defined positions on the aromatic rings. These localized structural characteristics are designed to interact specifically with amino acid residues in the Bcl-2 protein binding pocket, ensuring high selectivity for cancer cells over healthy cells and distinguishing the compounds from existing chemotherapeutic agents.
Data Source
AI summary
Compounds of formula (I):wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description.Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.